Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and basal ganglia disorders:

GPR55: A therapeutic target for Parkinson's disease? Celorrio M et al. Neuropharmacology. (2017)

Cannabidiol: a promising drug for neurodegenerative disorders? Iuvone T et al. CNS Neurosci Ther. (2009)

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Fernández-Ruiz J et al. Br J Clin Pharmacol. (2013)

Search results

Items: 1 to 20 of 29

1.

Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder.

Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Edden RAE, Williams S, Murphy DGM, Daly E, McAlonan GM.

Neuropsychopharmacology. 2019 Feb 6. doi: 10.1038/s41386-019-0333-8. [Epub ahead of print]

PMID:
30758329
2.

Novel inverse agonists for the orphan G protein-coupled receptor 6.

Laun AS, Shrader SH, Song ZH.

Heliyon. 2018 Nov 16;4(11):e00933. doi: 10.1016/j.heliyon.2018.e00933. eCollection 2018 Nov.

3.

GPR55: A therapeutic target for Parkinson's disease?

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS.

Neuropharmacology. 2017 Oct;125:319-332. doi: 10.1016/j.neuropharm.2017.08.017. Epub 2017 Aug 12.

PMID:
28807673
4.

Torsional stress promotes trinucleotidic expansion in spermatids.

Simard O, Niavarani SR, Gaudreault V, Boissonneault G.

Mutat Res. 2017 Aug;800-802:1-7. doi: 10.1016/j.mrfmmm.2017.04.001. Epub 2017 Apr 9.

PMID:
28412438
5.

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.

Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz J.

Int J Mol Sci. 2017 Mar 23;18(4). pii: E684. doi: 10.3390/ijms18040684.

6.

Severe motor and vocal tics controlled with Sativex®.

Trainor D, Evans L, Bird R.

Australas Psychiatry. 2016 Dec;24(6):541-544. Epub 2016 Aug 24.

PMID:
27558217
7.

Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.

Dos-Santos-Pereira M, da-Silva CA, Guimarães FS, Del-Bel E.

Neurobiol Dis. 2016 Oct;94:179-95. doi: 10.1016/j.nbd.2016.06.013. Epub 2016 Jun 29. No abstract available.

PMID:
27373843
8.

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

J Neurol. 2016 Jul;263(7):1390-400. doi: 10.1007/s00415-016-8145-9. Epub 2016 May 9.

PMID:
27159993
9.

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM.

Mol Pharmacol. 2016 Mar;89(3):364-75. doi: 10.1124/mol.115.101980. Epub 2015 Dec 23. Erratum in: Mol Pharmacol. 2016 Jun;89(6):694.

PMID:
26700564
10.

The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.

Santos NA, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RH, Santos AC.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):231-40. doi: 10.1016/j.tiv.2015.11.004. Epub 2015 Nov 7.

11.

[Cannabinoids in neurology--Brazilian Academy of Neurology].

Brucki SM, Frota NA, Schestatsky P, Souza AH, Carvalho VN, Manreza ML, Mendes MF, Comini-Frota E, Vasconcelos C, Tumas V, Ferraz HB, Barbosa E, Jurno ME.

Arq Neuropsiquiatr. 2015 Apr;73(4):371-4. doi: 10.1590/0004-282X20150041. Epub 2015 Apr 1. Portuguese.

12.

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA.

J Psychopharmacol. 2014 Nov;28(11):1088-98. doi: 10.1177/0269881114550355. Epub 2014 Sep 18.

PMID:
25237116
13.

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.

Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.

J Clin Pharm Ther. 2014 Oct;39(5):564-6. doi: 10.1111/jcpt.12179. Epub 2014 May 21.

PMID:
24845114
14.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

15.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x. Review.

16.

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):41-8. Review.

PMID:
22280340
17.

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x.

PMID:
22236282
18.

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.

J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14.

PMID:
21674569
19.

Prospects for cannabinoid therapies in basal ganglia disorders.

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Review.

20.

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.

García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J.

Br J Pharmacol. 2011 Aug;163(7):1495-506. doi: 10.1111/j.1476-5381.2011.01278.x.

Supplemental Content

Loading ...
Support Center